A newly discovered genetic effect may explain why some people see weaker blood sugar benefits from GLP-1 drugs like Ozempic. Credit: Shutterstock More than one-quarter of people with Type 2 diabetes now use GLP-1 receptor agonists, a class of medications that includes Ozempic. But new research from Stanford Medicine and international collaborators suggests these widely prescribed drugs may be less effective for some patients because of their genetics. The study found that about 10% of people